Print this page
-
A Phase II, open-label, multi-cohort, multicenter study in patients with unresectable HEPATOCELLULAR CARCINOMA and CHILDPUGH B7 and B8 Cirrhosis
Protocol: 072309Principal Investigator:
- Howard Hochster M.D (Rutgers University)
Applicable Disease Sites: Liver -
A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors.
Protocol: 072310Principal Investigator:
- Matthew Deek (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Rectum
Prostate
Small Intestine -
Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere ) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy.
Protocol: 072311Principal Investigator:
- Sharon Li (Rutgers University)
Applicable Disease Sites: Liver -
Phase 2 Study of Gemcitabine, Cisplatin, Quemliclustat (AB680) and Zimberelimab (AB122) during First-Line Treatment of Advanced Biliary Tract Cancers Big Ten Cancer Research Consortium BTCRC-GI22-564
Protocol: 072401Principal Investigator:
- Howard Hochster M.D (Rutgers University)
Applicable Disease Sites: Small Intestine -
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT).
Protocol: 111806Principal Investigator:
- Scott Moerdler M.D. (Rutgers University)
Applicable Disease Sites: Liver -
Colon Adjuvant Chemotherapy Based On Evaluation of Residual Disease.
Protocol: 072207Principal Investigator:
- Howard Hochster M.D (Rutgers University)
Applicable Disease Sites: Colon